Citations

Clear

3030 citation(s) found for "Susan, M".

APOE and immunity: Research highlights
Kloske, Courtney M. , Barnum, Christopher J. , Batista, André F., Bradshaw, Elizabeth M. , Bu, Guojun , Dennison, Jessica , Gearon, Mary D, Goate, Alison , Haass, Christian , Hu, William T. , Huggins, Lenique , Jones, Nahdia S. , Liddelow, Shane A. , Marsh, Samuel E. , Petersen, Melissa, Piña‐Escudero, Stefanie Danielle , Reiman, Eric M. , Sexton, Claire E. , TCW, Julia , Wallings, Rebecca L. , Weninger, Stacie, Wharton, Whitney , Wishard, Tyler J. , Worley, Susan, Carrillo, María C. , Sexton, Claire , Bu, Guojun , Goate, Alison M , Hu, William T. , Brickman, Adam M. , Heneka, Michael T. , Koldamova, Radosveta P. , Lemere, Cynthia Ann , Marcora, Edoardo , Nielsen, Henrietta M. , Petersen, Kellen K. , Petersen, Melissa , Qiu, Wei Qiao , Quiroz, Yakeel T. , Tansey, Malú G. , Teunissen, Charlotte E. , Tijms, Betty M. , Kant, Rik van der , Wilcock, Donna M. , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | March 28, 2023 | Volume: 19 | Issue: 6 | Pages: 2677-2696

10.1002/alz.13020 | PMID 36975090 Get It

AbstractINTRODUCTIONAt the Alzheimer's Association's APOE and Immunity virtual conference, held in October 2021, leading neuroscience experts shared recent research advances on and inspiring insights into the various roles that both the apolipoprotein E gene (APOE) and facets of immunity play in neurodegenerative diseases, including Alzheimer's disease and other dementias.METHODSThe meeting brought together more than 1200 registered attendees from 62 different countries, representing the realms of academia and industry.RESULTSDuring the 4‐day meeting, presenters illuminated aspects of the cross‐talk between APOE and immunity, with a focus on the roles of microglia, triggering receptor expressed on myeloid cells 2 (TREM2), and components of inflammation (e.g., tumor necrosis factor α [TNFα]).DISCUSSIONThis manuscript emphasizes the importance of diversity in current and future research and presents an integrated view of innate immune functions in Alzheimer's disease as well as related promising directions in drug development.
Whole Genome Analysis of Venous Thromboembolism: the Trans-Omics for Precision Medicine Program
Seyerle, Amanda A. , Laurie, Cecelia , Coombes, Brandon J. , Jain, Deepti , Conomos, Matthew P. , Brody, Jennifer A. , Chen, Ming‐Huei , Gogarten, Stephanie M. , Beutel, Kathleen M , Gupta, Namrata , Heckbert, Susan R. , Jackson, Rebecca D., Johnson, Andrew D. , McKnight, Barbara, Metcalf, Ginger , Morrison, Alanna C. , Reiner, Alex P. , Sofer, Tamar , Tang, Weihong , Program, Trans-Omics for Precision Medicine, Boerwinkle, Eric , Gabriel, Stacey , Gibbs, Richard A. , Laurie, Cathy C. , Rice, Kenneth , Pankow, James S. , Smith, Nicholas L. , Laurie, Cecelia A , Ko, Darae , Manson, JoAnn E , Metcalf, Ginger A , Morrison, Alanna C , Reiner, Alexander P , Sofer, Tamar , Tang, Weihong , Wiggins, Kerri L , Boerwinkle, Eric , de Andrade, Mariza , Laurie, Cathy C , Psaty, Bruce M , Vasan, Ramachandran S , Rice, Ken , Kooperberg, Charles , Pankow, James S , Smith, Nicholas L , Pankratz, Nathan , Brody, Jennifer A , Coombes, Brandon J , Rice, Kenneth , Manson, JoAnn E. , Wiggins, Kerri L. , Program, Trans-Omics for Precision Medicine, Andrade, Mariza de , Psaty, Bruce M. , Vasan, Ramachandran S. , Kooperberg, Charles , Pankratz, Nathan

Mayo Clinic

Circulation: Genomic and Precision Medicine | March 24, 2023 | Volume: 16 | Issue: 2 | Pages: No page available

10.1161/circgen.121.003532 | PMID 36960714 Get It

Background: Risk for venous thromboembolism has a strong genetic component. Whole genome sequencing from the TOPMed program (Trans-Omics for Precision Medicine) allowed us to look for new associations, particularly rare variants missed by standard genome-wide association studies. Methods: The 3793 cases and 7834 controls (11.6% of cases were individuals of African, Hispanic/Latino, or Asian ancestry) were analyzed using a single variant approach and an aggregate gene-based approach using our primary filter (included only loss-of-function and missense variants predicted to be deleterious) and our secondary filter (included all missense variants). Results: Single variant analyses identified associations at 5 known loci. Aggregate gene-based analyses identified only PROC (odds ratio, 6.2 for carriers of rare variants; P =7.4×10 −14 ) when using our primary filter. Employing our secondary variant filter led to a smaller effect size at PROC (odds ratio, 3.8; P =1.6×10 −14 ), while excluding variants found only in rare isoforms led to a larger one (odds ratio, 7.5). Different filtering strategies improved the signal for 2 other known genes: PROS1 became significant (minimum P =1.8×10 −6 with the secondary filter), while SERPINC1 did not (minimum P =4.4×10 −5 with minor allele frequency <0.0005). Results were largely the same when restricting the analyses to include only unprovoked cases; however, one novel gene, MS4A1 , became significant ( P =4.4×10 −7 using all missense variants with minor allele frequency <0.0005). Conclusions: Here, we have demonstrated the importance of using multiple variant filtering strategies, as we detected additional genes when filtering variants based on their predicted deleteriousness, frequency, and presence on the most expressed isoforms. Our primary analyses did not identify new candidate loci; thus larger follow-up studies are needed to replicate the novel MS4A1 locus and to identify additional rare variation associated with venous thromboembolism.
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Köbel, Martin , Kang, Eunyoung , Weir, Ashley , Rambau, Peter , Nelson, Gregg , Meagher, Nicola S. , Riggan, Marjorie J. , Alsop, Jennifer , Anglesio, Michael S. , Beckmann, Matthias W. , Bisinotto, Christiani, Boisen, M.M. , Boros, Jessica , Brand, Alison H. , Carney, Michael E. , Coulson, Penny , Courtney‐Brooks, Madeleine , Cushing‐Haugen, Kara L. , Deen, Suha , El‐Bahrawy, Mona , Group, AOCS, Fischer, Anna , Gayther, Simon A. , Hartmann, Arndt, Hendley, Joy , Huang, Yajue, Jimenez‐Liñan, Mercedes , Jones, Michael E. , Kennedy, Catherine J. , Kluz, Tomasz , Koziak, Jennifer M. , Lesnock, Jaime, Lester, Jenny , Longacre, Teri A. , Lycke, Maria , Mateoiu, Constantina , McCauley, Bryan M. , McGuire, Valerie , Ney, Britta, Olawaiye, Alexander , Oršulić, Sandra , Osório, Ana , Paz‐Ares, Luis , Rothstein, Joseph H. , Ruebner, Matthias , Shah, Mitul , Sharma, Raghwa , Shvetsov, Yurii B. , Singh, Naveena , Talhouk, Aline , Whittemore, Alice S. , Widschwendter, Martin , Bowtell, David D.L. , Reis, Francisco José Cândido dos , Fasching, Peter A. , García, María J. , Goodman, Marc T. , Goode, Ellen L. , Huntsman, David G. , Kelemen, Linda E. , Kommoss, Stefan , Le, Nhu D. , Menon, Usha , Schildkraut, Joellen M. , Sieh, Weiva , Staebler, Annette , Ramus, Susan J. , Anglesio, Michael S , Erber, Ramona , Gilks, C. Blake , Shvetsov, Yurii B , Campbell, Ian G , Huntsman, David G , Ramus, Susan J , Köbel, Martin , Menon, Usha , Kennedy, Catherine J , Widschwendter, Martin , Jones, Michael E , Sieh, Weiva , Brand, Alison H , Bowtell, David D , Nelson, Gregg S , El-Bahrawy, Mona A , Kluz, Tomasz , Goodman, Marc T , Kang, Eun‐Young, Lee, Cheng‐Han , Ghatage, Prafull , Brooks‐Wilson, Angela , Cybulski, Cezary , Elishaev, Esther , Fereday, Sián , Group, AOCS, Barquín, Arántzazu , Gentry‐Maharaj, Aleksandra , Gronwald, Helena , Grube, Marcel , Harnett, Paul R. , Harris, Holly R. , Hartkopf, Andreas D , Hein, Alexander , Hernandez, Brenda Y. , Jakubowska, Anna , Lubiński, Jan , Cajal, Teresa Ramón y , Schoemaker, Minouk J. , Sherman, Mark E. , Steed, Helen , Storr, Sarah J. , Traficante, Nadia , Wang, Chen , Wilkens, Lynne R. , Winham, Stacey J. , Benı́tez, Javier , Berchuck, Andrew , Campbell, Ian , Cook, Linda S. , DeFazio, Anna , Doherty, Jennifer A. , Fortner, Renée T. , Gronwald, Jacek , Karlan, Beth Y. , Martin, Stewart G. , Modugno, Francesmary , Pharoah, Paul D.P. , Sundfeldt, Karin , Swerdlow, Anthony J. , Brenton, James D.

Mayo Clinic

The Journal of Pathology: Clinical Research | March 22, 2023 | Volume: 9 | Issue: 3 | Pages: 208-222

10.1002/cjp2.311 | PMID 36948887 Get It

AbstractOur objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high‐grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi‐institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36–3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11–2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.
Endoscopic Endonasal Approach: Recurrent Fibrous Pituitary Adenoma with Cavernous Sinus Extension
Perez‐Vega, Carlos , Samson, Susan L. , Olomu, Osarenoma , Quiñones‐Hinojosa, Alfredo , Almeida, João Paulo

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1762525 Get It

Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Sperger, Jamie M. , Helzer, Kyle T. , Stahlfeld, Charlotte N. , Jiang, Dawei , Singh, Anupama , Kaufmann, Katherine R. , Niles, David J. , Héninger, Erika , Rydzewski, Nicholas R. , Wang, Liguo , Wang, Liewei , Yang, Rendong , Ren, Yanan , Kyriakopoulos, Christos E. , Slovin, Susan F. , Soule, Howard R. , Zhao, Shuang G. , Cai, Weibo , Dehm, Scott M. , Lang, Joshua M. , Engle, Jonathan W , Huang, Peng , Kyriakopoulos, Christos E , Slovin, Susan F , Soule, Howard R , Zhao, Shuang G , Kohli, Manish , Tagawa, Scott T , Cai, Weibo , Dehm, Scott M , Lang, Joshua M , Wang, Liguo , Engle, Jonathan W. , Kohli, Manish , Tagawa, Scott T.

Mayo Clinic

Clinical Cancer Research | March 20, 2023 | Volume: 29 | Issue: 12 | Pages: 2324-2335

10.1158/1078-0432.ccr-22-1305 | PMID 36939530 Get It

Abstract Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) frequently develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new therapies are needed. Trophoblastic cell-surface antigen (TROP-2) is a transmembrane protein identified in prostate cancer and overexpressed in multiple malignancies. TROP-2 is a therapeutic target for antibody–drug conjugates (ADC). Experimental Design: TROP-2 gene (TACSTD2) expression and markers of treatment resistance from prostate biopsies were analyzed using data from four previously curated cohorts of mCRPC (n = 634) and the PROMOTE study (dbGaP accession phs001141.v1.p1, n = 88). EPCAM or TROP-2–positive circulating tumor cells (CTC) were captured from peripheral blood for comparison of protein (n = 15) and gene expression signatures of treatment resistance (n = 40). We assessed the efficacy of TROP-2–targeting agents in a mouse xenograft model generated from prostate cancer cell lines. Results: We demonstrated that TACSTD2 is expressed in mCRPC from luminal and basal tumors but at lower levels in patients with neuroendocrine prostate cancer. Patients previously treated with ARSI showed no significant difference in TACSTD2 expression, whereas patients with detectable AR-V7 expression showed increased expression. We observed that TROP-2 can serve as a cell surface target for isolating CTCs, which may serve as a predictive biomarker for ADCs. We also demonstrated that prostate cancer cell line xenografts can be targeted specifically by labeled anti–TROP-2 agents in vivo. Conclusions: These results support further studies on TROP-2 as a therapeutic and diagnostic target for mCRPC.
Polygenic prediction of bipolar disorder in a Latin American sample
Cuéllar‐Barboza, Alfredo B. , Prieto, Miguel L. , Coombes, Brandon J. , Gardea‐Resendez, Manuel , Núñez, Nicolás A. , González, Sarai, Frye, Mark A. , Nunez, Nicolas, Cuellar-Barboza, Alfredo , Coombes, Brandon J , Gardea-Resendez, Manuel , Winham, Stacey J. , Romo‐Nava, Francisco , McElroy, Susan L. , Biernacka, Joanna M.

Mayo Clinic

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics | March 15, 2023 | Volume: 192 | Issue: 7-8 | Pages: 139-146

10.1002/ajmg.b.32936 | PMID 36919637 Get It

AbstractTo date, bipolar disorder (BD) genetic studies and polygenic risk scores (PRSs) for BD are based primarily on populations of European descent (EUR) and lack representation from other ancestries including Latin American (LAT). Here, we describe a new LAT cohort from the Mayo Clinic Bipolar Biobank (MCBB), a multisite collaboration with recruitment sites in the United States (EUR; 1,443 cases and 777 controls) and Mexico and Chile (LAT; 211 cases and 161 controls) and use the sample to explore the performance of a BD‐PRS in a LAT population. Using results from the largest genome‐wide association study of BD in EUR individuals, PRSice2 and LDpred2 were used to compute BD‐PRSs in the LAT and EUR samples from the MCBB. PRSs explained up to 1.4% (PRSice) and 4% (LDpred2) of the phenotypic variance on the liability scale in the LAT sample compared to 3.8% (PRSice2) and 3.4% (LDpred2) in the EUR samples. Future larger studies should further explore the differential performance of different PRS approaches across ancestries. International multisite studies, such as this one, have the potential to address diversity‐related limitations of prior genomic studies and ultimately contribute to the reduction of health disparities.
Machine Learning Models to Forecast Outcomes of Pituitary Surgery: A Systematic Review in Quality of Reporting and Current Evidence
Rech, Matheus Machado , Filho, Leonardo de Macêdo , White, Alexandra J. , Perez‐Vega, Carlos , Samson, Susan L. , Chaichana, Kaisorn L. , Olomu, Osarenoma , Quiñones‐Hinojosa, Alfredo , Almeida, João Paulo , Rech, Matheus M , de Macêdo Filho, Leonardo J M , Olomu, Osarenoma U, Samson, Susan L , Almeida, Joao Paulo

Mayo Clinic

Brain Sciences | March 15, 2023 | Volume: 13 | Issue: 3 | Pages: 495

10.3390/brainsci13030495 | PMID 36979305 Get It

Background: The complex nature and heterogeneity involving pituitary surgery results have increased interest in machine learning (ML) applications for prediction of outcomes over the last decade. This study aims to systematically review the characteristics of ML models involving pituitary surgery outcome prediction and assess their reporting quality. Methods: We searched the PubMed, Scopus, and Web of Knowledge databases for publications on the use of ML to predict pituitary surgery outcomes. We used the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) to assess report quality. Our search strategy was based on the terms “artificial intelligence”, “machine learning”, and “pituitary”. Results: 20 studies were included in this review. The principal models reported in each article were post-surgical endocrine outcomes (n = 10), tumor management (n = 3), and intra- and postoperative complications (n = 7). Overall, the included studies adhered to a median of 65% (IQR = 60–72%) of TRIPOD criteria, ranging from 43% to 83%. The median reported AUC was 0.84 (IQR = 0.80–0.91). The most popular algorithms were support vector machine (n = 5) and random forest (n = 5). Only two studies reported external validation and adherence to any reporting guideline. Calibration methods were not reported in 15 studies. No model achieved the phase of actual clinical applicability. Conclusion: Applications of ML in the prediction of pituitary outcomes are still nascent, as evidenced by the lack of any model validated for clinical practice. Although studies have demonstrated promising results, greater transparency in model development and reporting is needed to enable their use in clinical practice. Further adherence to reporting guidelines can help increase AI’s real-world utility and improve clinical practice.
Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD)
Wong, Annette , Mannix, Carly , Grantham, Jared J. , Allman‐Farinelli, Margaret , Badve, Sunil V. , Boudville, Neil , Byth, Karen , Chan, Jessie S. M., Coulshed, Susan, Edwards, Marie E., Fernando, Mangalee, Foster, Sheryl , Haloob, Imad, Harris, David C.H. , Hill, Julie, Howard, Kirsten , Howell, Martin , Jiang, Simon , Johnson, David W. , Kline, Timothy L. , Kumar, Karthik, Lee, Vincent , Lonergan, Maureen , Mai, Jun, McCloud, Philip , Peduto, Anthony , Rangan, Anna , Roger, Simon D. , Sud, Kamal , Torres, Vicente E. , Vliayuri, Eswari, Rangan, Gopala K. , Torres, Vincent, Torres, Vicente E , Johnson, David W , Howell, Martin , Lee, Vincent W , Rangan, Anna , Chan, Jessie, Erickson, Bradley J. , Hawley, Carmel M.

Mayo Clinic

BMJ Open | March 15, 2023 | Volume: 8 | Issue: 1 | Pages: e018794

10.1136/bmjopen-2017-018794 | PMID 29358433 Get It

Introduction Maintaining fluid intake sufficient to reduce arginine vasopressin (AVP) secretion has been hypothesised to slow kidney cyst growth in autosomal dominant polycystic kidney disease (ADPKD). However, evidence to support this as a clinical practice recommendation is of poor quality. The aim of the present study is to determine the long-term efficacy and safety of prescribed water intake to prevent the progression of height-adjusted total kidney volume (ht-TKV) in patients with chronic kidney disease (stages 1–3) due to ADPKD. Methods and analysis A multicentre, prospective, parallel-group, open-label, randomised controlled trial will be conducted. Patients with ADPKD (n=180; age ≤65 years, estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m 2 ) will be randomised (1:1) to either the control (standard treatment+usual fluid intake) or intervention (standard treatment+prescribed fluid intake) group. Participants in the intervention arm will be prescribed an individualised daily fluid intake to reduce urine osmolality to ≤270 mOsmol/kg, and supported with structured clinic and telephonic dietetic review, self-monitoring of urine-specific gravity, short message service text reminders and internet-based tools. All participants will have 6-monthly follow-up visits, and ht-TKV will be measured by MRI at 0, 18 and 36 months. The primary end point is the annual rate of change in ht-TKV as determined by serial renal MRI in control vs intervention groups, from baseline to 3 years. The secondary end points are differences between the two groups in systemic AVP activity, renal disease (eGFR, blood pressure, renal pain), patient adherence, acceptability and safety. Ethics and dissemination The trial was approved by the Human Research Ethics Committee, Western Sydney Local Health District. The results will inform clinicians, patients and policy-makers regarding the long-term safety, efficacy and feasibility of prescribed fluid intake as an approach to reduce kidney cyst growth in patients with ADPKD. Trial registration number ANZCTR12614001216606.
Abstract P584: The Impact of Multimorbidity and Functional Limitation on Mental Health and Quality of Life Among Patients With Heart Failure
Manemann, Sheila M., Haller, Irina V. , Horne, Benjamin D. , Roger, Véronique L. , Weston, Susan A., Killian, Jill M. , Hade, Erinn M. , Benziger, Catherine P. , Chamberlain, Alanna M.

Mayo Clinic

Circulation | March 14, 2023 | Volume: 147 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.147.suppl_1.p584 Get It

Background: Multimorbidity (MM) and functional limitation (FL) are associated with poor outcomes in heart failure (HF). However, the individual and combined effect of these on mental health and quality of life in patients with HF is not well understood. Methods: Patients aged ≥ 30 years with 2 or more HF diagnostic codes and 1 or more HF-related prescription drugs from four US institutions were mailed a survey to measure functional status (activities of daily living [ADLs]), quality of life and mental health (PROMIS-29 Health Profile) and social support (PROMIS Informational Support, Instrumental Support, and Social Isolation Short Forms). The sampling frame was restricted to patients with a first ever-diagnosis of HF on or after 1/1/2013 at 1 of the participating sites and on or after 1/1/2015 for the other 3 participating sites. A total of 3330 patients returned the survey (response rate 35%); among these, 3020 completed the questions of interest for this analysis and were retained. MM was defined as the presence of ≥ 2 non-cardiovascular comorbidities, and FL was defined as reporting any limitation in at least 1 of 8 ADLs. Patients were categorized into 4 groups by MM (Yes/No) and FL (Yes/No). We dichotomized the subscale scores of the PROMIS-29 at the median and calculated odd ratios for the 4 MM/FL groups. Results: Among 3020 patients with HF (45% female; mean age 73±12 years), 29% had neither MM or FL, 24% had MM only, 22% had FL only, and 25% had both. After adjustment, having both MM and FL or only FL was associated with increased odds of higher anxiety, depression, fatigue, sleep, and pain scores compared to having neither (Figure); having MM only was associated with a higher pain score. Conclusions: Patients with both FL and MM and only FL have similar odds of poor mental health and quality of life scores, underscoring the importance of the role that FL plays in outcomes in patients with HF.
Abstract P179: Development and Implementation of a Large, Multi-Center Survey of Patients With Heart Failure
Haller, Irina V. , Horne, Benjamin D. , Killian, Jill M. , Weston, Susan A., Manemann, Sheila M., Roger, Véronique L. , Chamberlain, Alanna M. , Hade, Erinn M. , Benziger, Catherine P.

Mayo Clinic

Circulation | March 14, 2023 | Volume: 147 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.147.suppl_1.p179 Get It

Background: Most patients with heart failure (HF) have multimorbidity which may cause difficulties with self-management. Understanding the determinants of successful self-management and the resources patients draw upon to effectively manage their health is fundamental to designing new practice models to improve outcomes in HF. Methods: We developed a survey guided by the Chronic Care Model to understand the distribution of patient-centric factors, including health literacy, social support, self-management, and functional and mental status in patients with HF. The survey was administered to HF patients from 4 health care systems participating in PCORnet® (the National Patient-Centered Clinical Research Network). Patients were identified utilizing data available in the PCORnet common data model on or after 1/1/2013 at 1 health system and on or after 1/1/2015 at 3 health systems: age ≥30 years, ≥2 HF diagnostic codes, and ≥1 HF-related prescription (positive predictive value of algorithm: 81%). Results: A total of 10,662 patients with HF were identified, 9684 were mailed a survey, and 3330 completed a survey (response rate: 35%). Responders were older than non-responders (74 vs. 71 years), less racially diverse (3% vs. 12% non-White), less likely to have reduced ejection fraction (EF; 22% vs. 27% with EF <40%), and had higher prevalence of most chronic conditions. Responders reported their health was generally good or fair, they frequently had cardiovascular comorbidities, more than half had difficulty climbing stairs, and more than 10% reported difficulties with bathing, preparing meals, and using transportation (Table). Nearly 80% of patients had family or friends sit with them during a doctor visit, and most (54%) manage their health by themselves. Conclusion: More than half of patients with HF manage their health by themselves even though most bring someone along to their health care appointments. Increased understanding of self-management resources may guide the development of interventions to improve HF outcomes.